hat
US manje ak dwòg administrasyon an jodi a apwouve Vosevi nan trete adilt ki gen C viris kwonik epatit (HCV) jenotip 1-6 san yo pa siwoz (maladi fwa) oswa avèk siwoz grav. Vosevi se yon fiks dòz, grenn konbinezon ki gen de dwòg deja apwouve - sofosbuvir ak velpatasvir - ak yon dwòg nouvo, voxilaprevir. Vosevi se tretman an premye apwouve pou pasyan ki te deja trete yo ak sofosbuvir an dirèk-aji antiviral dwòg oswa lòt dwòg pou HCV ki anpéché yon pwoteyin ki rele NS5A.
eng
The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A.